CYP2C19 Drug Exposure Is Pervasive After Stroke

This cohort quantifies how often stroke patients receive non-antiplatelet CYP2C19-metabolized drugs, arguing that genotype results obtained for clopidogrel selection carry broad, durable value across a patient's medication list.

clopidogrelproton pump inhibitorsSSRIstricyclic antidepressantsCYP2C19pharmacogenomicsstroketransient ischaemic attackantiplatelet therapycohort studymedicines optimization Clinical Pharmacy Practice

Background Information

CYP2C19 genotype testing extends beyond antiplatelet use in stroke patients.

CYP2C19 genotype testing can inform the prescribing of both antiplatelet and non-antiplatelet drugs after stroke, impacting patient care. 81% of stroke patients were co-prescribed a CYP2C19-metabolized drug at discharge, increasing to 83% in follow-up, highlighting the relevance of genotype-informed prescribing. CYP2C19 genotype testing at discharge may guide broader prescribing beyond antiplatelets, especially with increasing drug exposure over time. CYP2C19 genotype testing may guide more extensive prescribing decisions post-stroke.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Swire CC, Lambarth AT, Saleem A, Burrage DR

Citation: Swire CC, Lambarth AT, Saleem A, et al. Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing. British journal of clinical pharmacology. 2026. doi:10.1002/bcp.70722

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →